VF
OREX

Virtu Financial’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Virtu Financial’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-50,290
Closed -$65K – 3148
2017
Q4 		$65K Buy
50,290
+20,591
+69% +$33.5K ﹤0.01% 2028
2017
Q3 		$63K Buy
+29,699
New +$72.5K ﹤0.01% 2192

Other funds holding OREX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
OWIM
Old West Investment Management Los Angeles, California $923M AUM 112.31% 1-Year Est. Return
TI
Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Virtu Financial's OREX Position: Q1 2018 in Review

Virtu Financial sold out of Orexigen Therapeutics, Inc. (OREX) in Q1 2018, closing a stake of 50,290 shares — an estimated $65K sold.

Virtu Financial first reported a position in OREX in Q3 2017 and held it in 2 quarters. The position peaked at $65K in Q4 2017. 27 funds tracked by Wall St. Rank hold OREX as of Q1 2018.

  • Virtu Financial reported no remaining Orexigen Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • Virtu Financial sold 50,290 Orexigen Therapeutics, Inc. shares in Q1 2018, an estimated $65K.
  • Virtu Financial first reported a position in Orexigen Therapeutics, Inc. in Q3 2017 and held it in 2 quarters.
  • Virtu Financial's Orexigen Therapeutics, Inc. position peaked at $65K in Q4 2017.
  • 27 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q1 2018.

Based on Virtu Financial's 13F filing for Q1 2018, filed 14 May 2018.